Latin America: Markets in Advanced Wound Closure

2 Min Read

In the Americas, the U.S. dominates all medtech markets, but as manufacturers seek the “low hanging fruit” of readily available market opportunities, Latin America rises to the fore, with its large populations, proximity to existing distribution, lower manufacturing costs and other advantages.  Brazil and Mexico are the biggest opportunities as reflected in the revenues generated there in the sale of medtech products.

In the Americas, the U.S. dominates all medtech markets, but as manufacturers seek the “low hanging fruit” of readily available market opportunities, Latin America rises to the fore, with its large populations, proximity to existing distribution, lower manufacturing costs and other advantages.  Brazil and Mexico are the biggest opportunities as reflected in the revenues generated there in the sale of medtech products.

The large and growing market for advanced wound closure products — encompassing hemostats, fibrin sealants, high-strength adhesives/glues and post-surgical adhesion prevention — is reflected in Latin America.  Below is the market for these advanced products in Latin America:

Source: Report #S180, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015”.

A similar distribution of wound closure revenues across these countries is found for traditional wound closure products (sutures, staples and other mechanical closure), with the dominant category being sutures and staples.

     

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version